Fisher Bioservices Inc.

Fisher Bioservices Inc. Clinical Trials Division, a subsidiary of Fisher Clinical Services Inc. (itself a child of Thermo Electron Corporation), provides biorepository management, specimen storage, cold-chain logistics, and related scientific services to federal research agencies as a prime contractor (96% of recent awards) and does not compete under small-business set-asides. The division operates across multiple storage environments including ultra-low freezers (-80°C), liquid nitrogen tanks, and refrigerated facilities, serving a $2.2 billion combined potential value portfolio spanning 536 recent awards to 37 distinct federal agencies.

Customer concentration sits heavily with National Institutes of Health institutes. The top five funding agencies account for 77% of combined potential value, anchored by the National Institute of Allergy and Infectious Diseases (41 awards, $720.6 million), the National Cancer Institute (82 awards, $550 million), and the National Institute of Child Health and Human Development (96 awards, $261 million). NIAID's volume-to-value split is notable — 41 awards by count represent a smaller fraction than the dollar magnitude suggests, reflecting larger individual contract vehicles. The Department of the Army ranks fifth by award count (25 awards) but drops outside the top five by potential value, while NIDA (23 awards, $54.7 million) appears in the top five by dollars.

Fisher Bioservices operates multiple parent indefinite-delivery and supply-schedule vehicles. The GSA Federal Supply Schedule (Special Item Number 541380, Testing Laboratories) carries 175 task orders valued at $29.8 million under a ceiling of $30.3 million through August 2030. The division anchors single-award IDIQs with NICHD ($100 million biospecimen repository, January 2025 through January 2035), NIAID for interventional agents chemistry ($50 million, September 2025 through September 2032), Naval Sea Systems Command for engineering and dosimetry systems ($189 million, June 2025 through June 2030), and the National Cancer Institute for preclinical chemical and drug storage ($19 million, March 2023 through February 2028). A $48 million multiple-award IDIQ with NIAID for vaccine manufacturing services (awarded September 2026) and a $49.9 million IDIQ with the National Institute on Drug Abuse for chemistry, manufacturing, and controls services (awarded August 2024) round out the vehicle portfolio. Indefinite Delivery Contract HHSN275201400003I carries 61 task orders valued at $27.9 million; IDC 75N94025D00002 (a Naval Sea Systems Command parent) carries 16 task orders at $65.1 million combined value.

Representative prime work demonstrates the division's core capability footprint. A $36.96 million delivery order from NICHD (July 2026) covers repository services for the DASH Biobank through July 2036 under cost-plus-fixed-fee pricing. A $38.1 million cost-plus-fixed-fee contract from the National Cancer Institute (February 2023 through January 2028) covers receiving, storage, maintenance at controlled temperature and humidity, and distribution of clinical agents in support of cancer clinical trials, with hazardous and biologic materials handling and FDA-compliant record-keeping. A $29.4 million definitive contract from NIAID (September 2022 through September 2027) calls for clinical materials services—receiving, storing, packaging, shipping, testing, and disposing of clinical agents and specimens—with initial transfer of 1 million vials of specimens and 500,000 vials of product, serving up to 100 clinical trials domestically and internationally. A $15.4 million delivery order from Naval Sea Systems Command (June 2025) covers engineering services and dosimetry system support under a $189 million IDIQ, performed in Bedford, Ohio. A CDC definitive contract (September 2022 through March 2027) valued at $2.42 million provides bioreository services for the National Center on Birth Defects and Developmental Disabilities, covering transfer, storage, shipment, and inventory management of specimens from the National Birth Defects Prevention Study and Division of Blood Disorders projects.

Recent activity has grown modestly — from 14 awards in 2022 to 24 in 2025, then 17 in 2026 — with thirteen awards (combined potential value $188.4 million) reaching ultimate completion in the next twenty-four months, creating recompete exposure across NICHD biospecimen repositories, NIAID clinical materials, and NCI preclinical chemistry storage.

SCI-reported invoicing on federal service contracts above the $150,000 threshold totaled $113.5 million across FY2022–FY2025, with $24.6 million in FY2022, $38.1 million in FY2023, $24.7 million in FY2024, and $26.2 million in FY2025. FTE reporting from SCI shows a sharp drop from 210 FTEs in FY2022 (reflecting contract-level workforce aggregation) to 56.8 in FY2023, holding around 54–62 FTEs in FY2024–FY2025. Government-paid hourly rates on SCI-reportable prime contracts ran a median of $169.17 per hour, with rates spanning from $61.10 at the tenth percentile to $665.28 at the ninety-percentile, reflecting a mixed labor portfolio of technical specimens handlers and senior scientific staff. Across SCI-reportable prime contracts, subcontractors account for zero percent of total contractor hours; the division self-performs substantially all work with minimal named subcontractor engagement (two total subcontractors named across the SCI dataset).

In its subcontractor role, Fisher Bioservices delivers biospecimen storage and specimen management to the International AIDS Vaccine Initiative on vaccine development programs for Marburg and Sudan ebolavirus candidates, providing long-term GMP storage and distribution of drug products. The division also subcontracts to Wake Forest University Health Sciences on the Women's Health Initiative Clinical Coordinating Center, managing over 5 million vials in ultra-low freezers with 24/7/365 equipment monitoring and full disaster recovery infrastructure. Sub-awards to University of South Florida route through the Environmental Determinants of Diabetes in the Young (TEDDY) study and the Type 1 Diabetes TrialNet Data Coordinating Center.

Award activity concentrates in testing laboratories (NAICS 541380, 189 awards), research and development in physical and life sciences (65 awards), refrigerated warehousing and storage (58 awards), and biotechnology R&D (29 awards). PSC coding reflects the same footprint: Housekeeping/Warehousing and Storage (98 awards) and Health R&D Services/Applied Research (88 awards) anchor the portfolio, with maintenance and repair of laboratory equipment (62 awards) and professional support services (53 awards) filling secondary niches. Work is performed nationwide across Rockville, Maryland (primary operations center), Frederick, Maryland, Bedford, Ohio, Bethesda, Maryland, and Potomac, Maryland locations, supporting research infrastructure across NIH institutes, CDC, DoD, and BARDA.